Current Perspectives of convalescent plasma therapy in COVID-19

Main Article Content

Kamal Kant Sahu
Ajay Kumar Mishra
Manish Raturi
Amos Lal


coronavirus, covid19, Pandemic, convalescent plasma, Plasma therapy


The outbreak of the coronavirus disease 2019 (COVID‐19) has posed an unprecedented challenge to the health care communities across the globe. As of June 2, 2020, a total of 6,418,968 confirmed COVID-19 cases with 378,954 deaths have been reported. Different regions of the world have reported varying intensity of COVID-19 severity. The disease burden for COVID-19 depends on multiple factors like the local infection rate, susceptible population, mortality rate, and so on. The COVID-19 pandemic is a rapidly evolving emergency and is a subject of regular debate and advanced research. As of today, there is a lack of definitive treatment options for COVID-19 pneumonia. In search of alternative options, few drugs are being tested for their efficacy and repurposing. Preliminary reports have shown positive outcomes with Remdesivir and tocilizumab, but this needs further confirmation. Recently, the therapeutic application of Convalescent Plasma therapy in critically ill patients suffering from COVID-19 has gained momentum. We hereby discuss the convalescent plasma as a potential therapeutic option, its challenges of finding the ideal donors, transfusion medicine responsibilities, and the current global experience with its use.


Download data is not yet available.


Metrics Loading ...
Abstract 88 |


1. Sahu KK, Mishra AK and Lal A. COVID-2019: update on epidemiology, disease spread and management. Monaldi Archives for Chest Disease 2020; 90.
2. Sahu KK, Mishra AK and Lal A. Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV). Annals of Translational Medicine 2020.
3. Sahu KK, Mishra AK and Lal A. Comprehensive update on current outbreak of novel coronavirus infection (2019-nCoV). Annals of Translational Medicine 2020; 8.
4. Sahu KK, Lal A and Mishra AK. Latest updates on COVID‐2019: A changing paradigm shift. Journal of medical virology 2020.
5. Wu Z and McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239-1242. DOI: 10.1001/jama.2020.2648.
6. Yang M, Shang Y-x, Tian Z-y, et al. Characteristics of registered studies for Coronavirus disease 2019 (COVID-19): A systematic review. Integrative Medicine Research 2020: 100426.
7. Borku Uysal B, Ikitimur H, Yavuzer S, et al. ''Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid‐19 pneumonia patients''. Journal of medical virology.
8. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends 2020; 14: 69-71.
9. Sahu KK, Jindal V, Siddiqui AD, et al. Convalescent Plasma Therapy: A Passive Therapy for An Aggressive COVID‐19. Journal of medical virology 2020.
10. Valk SJ, Piechotta V, Chai KL, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a rapid review. Cochrane Database of Systematic Reviews 2020.
11. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. Jama 2020; 323: 1582-1589.
12. Sahu KK and Kumar R. Preventive and treatment strategies of COVID-19: From community to clinical trials. Journal of family medicine and primary care 2020; 9: 2149.
13. Asfahan S, Deokar K, Dutt N, et al. Extrapolation of mortality in COVID-19: Exploring the role of age, sex, co-morbidities and health-care related occupation. Monaldi Archives for Chest Disease 2020; 90.
14. Ambrosino I, Barbagelata E, Ortona E, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Arch Chest Dis 2020; 90 2020/05/26. DOI: 10.4081/monaldi.2020.1389.
15. Sahu KK, Mishra AK, Lal A, et al. India Fights Back: COVID-19 Pandemic. Heart & Lung: The Journal of Cardiopulmonary and Acute Care 2020.
16. Sahu KK, Mishra AK and Lal A. A twin challenge to handle: COVID‐19 with pregnancy. Journal of medical virology 2020.
17. Sahu KK, Lal A and Mishra AK. COVID‐2019 and Pregnancy: a plea for transparent reporting of all cases. Acta obstetricia et gynecologica Scandinavica 2020.
18. Sahu KK, Siddiqui AD and Cerny J. Managing Sickle Cell Patients With COVID‐19 Infection: The Need to Pool Our Collective Experience. British Journal of Haematology 2020.
19. Sahu KK, Mishra AK and Lal A. Re: From the frontlines of COVID-19-How prepared are we as obstetricians: A commentary. Bjog 2020 2020/05/07. DOI: 10.1111/1471-0528.16257.
20. Jindal V, Sahu KK, Gaikazian S, et al. Cancer treatment during COVID-19 pandemic. Medical Oncology (Northwood, London, England) 2020; 37.
21. Sahu KK, Siddiqui AD and Cerny J. COVID-19 pandemic and impact on hematopoietic stem cell transplantation. Bone Marrow Transplantation 2020: 1-3.
22. Sahu KK, Jindal V, Siddiqui AD, et al. Facing COVID-19 in the hematopoietic cell transplant setting: A new challenge for transplantation physicians. Blood Cells, Molecules & Diseases 2020.
23. Sahu KK, Jindal V and Siddiqui AD. Managing COVID-19 in Patients With Cancer: A Double Blow for Oncologists. American Society of Clinical Oncology, 2020.
24. Soy M, Keser G, Atagündüz P, et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology 2020: 1.
25. Lal A, Mishra AK and Sahu KK. CT chest findings in coronavirus disease-19 (COVID-19). J Formos Med Assoc 2020 2020/04/09. DOI: 10.1016/j.jfma.2020.03.010.
26. Sahu KK, Lal A and Mishra AK. An update on CT chest findings in coronavirus disease-19 (COVID-19). Heart Lung 2020 2020/03/25. DOI: 10.1016/j.hrtlng.2020.03.007.
27. Sahu KK, Mishra AK, Martin K, et al. COVID-19 and clinical mimics. Correct diagnosis is the key to appropriate therapy. Monaldi Archives for Chest Disease 2020; 90.
28. Lal A, Davis MJ, Akhtar J, et al. Serious Cover-Up: Hodgkin's Lymphoma Masked by Organizing Pneumonia. Am J Med 2018; 131: 1174-1177. 2018/04/17. DOI: 10.1016/j.amjmed.2018.03.019.
29. Akella P, Loganathan S, Jindal V, et al. Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. Respir Med Case Rep 2019; 26: 17-22. 2018/11/21. DOI: 10.1016/j.rmcr.2018.11.005.
30. Lal A, Akhtar J, Isaac S, et al. Unusual cause of chest pain, Bornholm disease, a forgotten entity; case report and review of literature. Respir Med Case Rep 2018; 25: 270-273. 2018/10/27. DOI: 10.1016/j.rmcr.2018.10.005.
31. Lal A, Pena ED, Sarcilla DJ, et al. Ideal Length of Oral Endotracheal Tube for Critically Ill Intubated Patients in an Asian Population: Comparison to Current Western Standards. Cureus 2018; 10: e3590. 2019/01/25. DOI: 10.7759/cureus.3590.
32. Lal A, Akhtar J, Pinto S, et al. Recurrent Pulmonary Embolism and Hypersensitivity Pneumonitis Secondary to Aspergillus, in a Compost Plant Worker: Case Report and Review of Literature. Lung 2018; 196: 553-560. 2018/07/22. DOI: 10.1007/s00408-018-0142-6.
33. Lal A, Akhtar J, Ullah A, et al. First Case of Pleural Empyema Caused by Staphylococcus simulans: Review of the Literature. Case Rep Infect Dis 2018; 2018: 7831284. 2018/11/09. DOI: 10.1155/2018/7831284.
34. Lal A, Akhtar J, Khan MS, et al. Primary endobronchial amyloidosis: A rare case of endobronchial tumor. Respir Med Case Rep 2018; 23: 163-166. 2018/05/03. DOI: 10.1016/j.rmcr.2018.02.007.
35. Lal A, Mishra AK, Sahu KK, et al. Spontaneous Pneumomediastinum: Rare Complication of Tracheomalacia. Archivos de bronconeumologia 2020; 56: 185-186. 2019/11/15. DOI: 10.1016/j.arbres.2019.09.017.
36. Mishra AK, Sahu KK, Lal A, et al. Mechanisms of stroke and the role of anticoagulants in COVID-19. J Formos Med Assoc 2020 2020/07/02. DOI: 10.1016/j.jfma.2020.06.026.
37. Sahu KK, Mishra AK and Lal A. Trajectory of the COVID-19 pandemic: chasing a moving target. Annals of translational medicine 2020; 8: 694-694. DOI: 10.21037/atm-20-2793.
38. Mishra AK, George AA and Sargent J. Letter to the Editor Regarding "Acute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic: From Trough of Disillusionment to Slope of Enlightenment". World neurosurgery 2020: S1878-8750(1820)31369-31363. DOI: 10.1016/j.wneu.2020.06.111.
39. Mishra AK, Sahu KK, George AA, et al. Cerebrovascular events in COVID-19 patients. Monaldi Arch Chest Dis 2020; 90 2020/06/13. DOI: 10.4081/monaldi.2020.1341.
40. Mishra AK, Lal A, Sahu KK, et al. Mechanisms of neurological injury in COVID -19. World neurosurgery 2020 2020/05/20. DOI: 10.1016/j.wneu.2020.05.089.
41. Mishra AK, Sahu KK, Lal A, et al. Patterns of heart Injury in COVID–19 and relation to outcome. Journal of medical virology 2020.
42. Mishra AK, Sahu KK and Lal A. Reporting of all cardiac medications and their outcome in COVID - 19. Journal of medical virology 2020 2020/04/09. DOI: 10.1002/jmv.25843.
43. Mishra AK, Sahu KK, George AA, et al. A review of cardiac manifestations and predictors of outcome in patients with COVID–19. Heart & Lung 2020.
44. Sahu KK and Siddiqui AD. From Hematologistʼs desk: The effect of COVID‐19 on the blood system. American Journal of Hematology 2020.
45. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44-46. 2004/12/24. DOI: 10.1007/s10096-004-1271-9.
46. Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging infectious diseases 2016; 22: 1554.
47. Memish ZA, Perlman S, Van Kerkhove MD, et al. Middle East respiratory syndrome. Lancet 2020; 395: 1063-1077. 2020/03/08. DOI: 10.1016/s0140-6736(19)33221-0.
48. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of internal medicine 2006; 145: 599-609. 2006/08/31. DOI: 10.7326/0003-4819-145-8-200610170-00139.
49. Ko J-H, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antiviral therapy 2018; 23: 617-622.
50. Fischer JC, Zänker K, van Griensven M, et al. The role of passive immunization in the age of SARS-CoV-2: an update. European Journal of Medical Research 2020; 25: 1-6.
51. Rajendran K, Narayanasamy K, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review. Journal of medical virology 2020.
52. Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Reviews 2020: 102554.
53. Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 Patients with Convalescent Plasma. The American Journal of Pathology 2020.
54. Sahu KK, Mishra AK and Lal A. COIVD 19 Disease: Tackling a pandemic in 21st Century. QJM : monthly journal of the Association of Physicians 2020 2020/04/09. DOI: 10.1093/qjmed/hcaa117.
55. Food U and Administration D. Recommendations for investigational COVID-19 convalescent plasma. May, 2020.
56. Duan K, Liu B, Li C, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv 2020.
57. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020.
58. Ahn JY, Sohn Y, Lee SH, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean medical science 2020; 35.
59. Zeng Q-L, Yu Z-J, Gou J-J, et al. Effect of convalescent plasma therapy on viral shedding and survival in COVID-19 patients. The Journal of Infectious Diseases 2020.
60. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China. Journal of medical virology 2020.
61. Raturi M and Kusum A. The active role of a blood center in outpacing the transfusion transmission of COVID-19. Transfusion Clinique et Biologique 2020; 27: 96.
62. Raturi M, Shastry S, Murugesan M, et al. Effect of plasma component transfusion on conventional coagulation screening tests. Asian journal of transfusion science 2018; 12: 57.
63. Roback JD and Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. Jama 2020; 323: 1561-1562.
64. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: m1256. 2020/03/29. DOI: 10.1136/bmj.m1256.
65. Lal A, Nabzdyk C, Ramakrishna H, et al. Consider Heightened Awareness of Propofol Infusion Syndrome after Extracorporeal Membrane Oxygenation (ECMO) Decannulation. Journal of Cardiothoracic and Vascular Anesthesia 2019. DOI:
66. Lal A, Akhtar J, Jindal V, et al. Rare Cause of Respiratory Failure: A Twist in the Tale. Annals of the American Thoracic Society 2018; 15: 880-883. 2018/06/30. DOI: 10.1513/AnnalsATS.201802-122CC.
67. Sai K, Lal A, Lakshmi Maradana J, et al. Hypokalemia associated with mifepristone use in the treatment of Cushing's syndrome. Endocrinol Diabetes Metab Case Rep 2019; 2019 2019/11/20. DOI: 10.1530/edm-19-0064.
68. Lal A, Mishra AK and Sahu KK. Prevention of Early Ventilator-Associated Pneumonia. The New England journal of medicine 2020; 382: 1671-1672. 2020/04/23. DOI: 10.1056/NEJMc2001183.
69. Anudeep T, Jeyaraman M, Shetty DU, et al. Convalescent Plasma as a plausible therapeutic option in nCOVID-19–A Review. J Clin Trials 2020; 10: 1000409.
70. Giannis D, Ziogas IA and Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 2020; 127: 104362. 2020/04/20. DOI: 10.1016/j.jcv.2020.104362.
71. Watson GA, Sperry JL, Rosengart MR, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. Journal of Trauma and Acute Care Surgery 2009; 67: 221-230.
72. Lyons WS. Fresh Frozen Plasma Is Not Independently Associated With a Higher Risk of Multiple Organ Failure and Acute Respiratory Distress Syndrome. Journal of Trauma and Acute Care Surgery 2010; 68: 749.